Mitchell Reed Smith, Opeyemi Jegede, Peter Martin, Brian Till, Samir Parekh, David T Yang, Eric D Hsi, Thomas E Witzig, Sandeep S Dave, David W Scott, Curtis A Hanson, Lale Kostakoglu, Nizar N Abdel Samad, Carla Casulo, Nancy L Bartlett, Paolo F Caimi, Tareq Al Baghdadi, Kristie Blum, Mark Romer, David J Inwards, Rachel Lerner, Lynne Wagner, Richard F Little, Jonathan W Friedberg, John P Leonard, Brad S Kahl
While initial therapy of mantle cell lymphoma (MCL) is not standardized, bendamustine-rituximab (BR) is commonly used in older patients. Rituximab (R) maintenance following induction is often utilized. Thus, the open-label, randomized phase II ECOG-ACRIN Cancer Research Group E1411 trial was designed to test two questions: 1) Does addition of bortezomib to BR induction (BVR) and/or 2) addition of lenalidomide to rituximab (LR) maintenance improve progression-free survival (PFS) in patients with treatment-naïve MCL? From 2012-2016, 373 previously untreated patients, 87% ≥ 60 years old, were enrolled in this trial...
May 31, 2024: Blood